{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T07:03:56Z","timestamp":1792047836337,"version":"4.4.0"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,10,27]],"date-time":"2023-10-27T00:00:00Z","timestamp":1698364800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,10,27]],"date-time":"2023-10-27T00:00:00Z","timestamp":1698364800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Commun Biol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Deficiency in human mature frataxin (hFXN-M) protein is responsible for the devastating neurodegenerative and cardiodegenerative disease of Friedreich\u2019s ataxia (FRDA). It results primarily through epigenetic silencing of the\n                    <jats:italic>FXN<\/jats:italic>\n                    gene by GAA triplet repeats on intron 1 of both alleles. GAA repeat lengths are most commonly between 600 and 1200 but can reach 1700. A subset of approximately 3% of FRDA patients have GAA repeats on one allele and a mutation on the other. FRDA patients die most commonly in their 30s from heart disease. Therefore, increasing expression of heart hFXN-M using gene therapy offers a way to prevent early mortality in FRDA. We used rhesus macaque monkeys to test the pharmacology of an adeno-associated virus (AAV)hu68.CB7.hFXN therapy. The advantage of using non-human primates for hFXN-M gene therapy studies is that hFXN-M and monkey FXN-M (mFXN-M) are 98.5% identical, which limits potential immunologic side-effects. However, this presented a formidable bioanalytical challenge in quantification of proteins with almost identical sequences. This could be overcome by the development of a species-specific quantitative mass spectrometry-based method, which has revealed for the first time, robust transgene-specific human protein expression in monkey heart tissue. The dose response is non-linear resulting in a ten-fold increase in monkey heart hFXN-M protein expression with only a three-fold increase in dose of the vector.\n                  <\/jats:p>","DOI":"10.1038\/s42003-023-05472-z","type":"journal-article","created":{"date-parts":[[2023,10,27]],"date-time":"2023-10-27T14:03:03Z","timestamp":1698415383000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Quantification of human mature frataxin protein expression in nonhuman primate hearts after gene therapy"],"prefix":"10.1038","volume":"6","author":[{"given":"Teerapat","family":"Rojsajjakul","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juliette J.","family":"Hordeaux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gourav R.","family":"Choudhury","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian J.","family":"Hinderer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clementina","family":"Mesaros","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9630-3131","authenticated-orcid":false,"given":"James M.","family":"Wilson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0366-8658","authenticated-orcid":false,"given":"Ian A.","family":"Blair","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,10,27]]},"reference":[{"key":"5472_CR1","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1126\/science.271.5254.1423","volume":"271","author":"V Campuzano","year":"1996","unstructured":"Campuzano, V. et al. Friedreich\u2019s ataxia: autosomal recessive disease caused by an intronic GAA triplet repeat expansion. Science 271, 1423\u20131427 (1996).","journal-title":"Science"},{"key":"5472_CR2","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.neuint.2017.08.002","volume":"117","author":"S Chiang","year":"2018","unstructured":"Chiang, S., Kalinowski, D. S., Jansson, P. J., Richardson, D. R. & Huang, M. L.-H. Mitochondrial dysfunction in the neuro-degenerative and cardio-degenerative disease, Friedreich\u2019s ataxia. Neurochem Int. 117, 35\u201348 (2018).","journal-title":"Neurochem Int."},{"key":"5472_CR3","doi-asserted-by":"publisher","first-page":"267","DOI":"10.2217\/nmt-2022-0011","volume":"12","author":"M Keita","year":"2022","unstructured":"Keita, M., McIntyre, K., Rodden, L. N., Schadt, K. & Lynch, D. R. Friedreich ataxia: clinical features and new developments. Neurodegener. Dis. Manag 12, 267\u2013283 (2022).","journal-title":"Neurodegener. Dis. Manag"},{"key":"5472_CR4","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1089\/ars.2009.3015","volume":"13","author":"R Santos","year":"2010","unstructured":"Santos, R. et al. Friedreich ataxia: molecular mechanisms, redox considerations, and therapeutic opportunities. Antioxid. Redox Signal 13, 651\u2013690 (2010).","journal-title":"Antioxid. Redox Signal"},{"key":"5472_CR5","doi-asserted-by":"publisher","first-page":"1534","DOI":"10.1093\/hmg\/ddm102","volume":"16","author":"I Condo","year":"2007","unstructured":"Condo, I. et al. In vivo maturation of human frataxin. Hum. Mol. Genet 16, 1534\u20131540 (2007).","journal-title":"Hum. Mol. Genet"},{"key":"5472_CR6","doi-asserted-by":"publisher","first-page":"3521","DOI":"10.1093\/hmg\/ddn244","volume":"17","author":"S Schmucker","year":"2008","unstructured":"Schmucker, S., Argentini, M., Carelle-Calmels, N., Martelli, A. & Puccio, H. The in vivo mitochondrial two-step maturation of human frataxin. Hum. Mol. Genet 17, 3521\u20133531 (2008).","journal-title":"Hum. Mol. Genet"},{"key":"5472_CR7","doi-asserted-by":"publisher","first-page":"36773","DOI":"10.1074\/jbc.M113.525857","volume":"288","author":"A Pandey","year":"2013","unstructured":"Pandey, A. et al. Frataxin directly stimulates mitochondrial cysteine desulfurase by exposing substrate-binding sites, and a mutant Fe-S cluster scaffold protein with frataxin-bypassing ability acts similarly. J. Biol. Chem. 288, 36773\u201336786 (2013).","journal-title":"J. Biol. Chem."},{"key":"5472_CR8","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms6686","volume":"6","author":"A Parent","year":"2015","unstructured":"Parent, A. et al. Mammalian frataxin directly enhances sulfur transfer of NFS1 persulfide to both ISCU and free thiols. Nat. Commun. 6, 5686 (2015).","journal-title":"Nat. Commun."},{"key":"5472_CR9","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-017-01497-1","volume":"8","author":"MT Boniecki","year":"2017","unstructured":"Boniecki, M. T., Freibert, S. A., Muhlenhoff, U., Lill, R. & Cygler, M. Structure and functional dynamics of the mitochondrial Fe\/S cluster synthesis complex. Nat. Commun. 8, 1287 (2017).","journal-title":"Nat. Commun."},{"key":"5472_CR10","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-11470-9","volume":"10","author":"S Gervason","year":"2019","unstructured":"Gervason, S. et al. Physiologically relevant reconstitution of iron-sulfur cluster biosynthesis uncovers persulfide-processing functions of ferredoxin-2 and frataxin. Nat. Commun. 10, 3566 (2019).","journal-title":"Nat. Commun."},{"key":"5472_CR11","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1038\/mt.2015.41","volume":"23","author":"Y Li","year":"2015","unstructured":"Li, Y. et al. Excision of Expanded GAA Repeats Alleviates the Molecular Phenotype of Friedreich\u2019s Ataxia. Mol. Ther. 23, 1055\u20131065 (2015).","journal-title":"Mol. Ther."},{"key":"5472_CR12","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.1056\/NEJM199610173351601","volume":"335","author":"A Durr","year":"1996","unstructured":"Durr, A. et al. Clinical and genetic abnormalities in patients with Friedreich\u2019s ataxia. N. Engl. J. Med. 335, 1169\u20131175 (1996).","journal-title":"N. Engl. J. Med."},{"key":"5472_CR13","doi-asserted-by":"publisher","first-page":"874768","DOI":"10.3389\/fnins.2022.874768","volume":"16","author":"Q Wang","year":"2022","unstructured":"Wang, Q. et al. Simultaneous Quantification of Mitochondrial Mature Frataxin and Extra-Mitochondrial Frataxin Isoform E in Friedreich\u2019s Ataxia Blood. Front. Neurosci. 16, 874768 (2022).","journal-title":"Front. Neurosci."},{"key":"5472_CR14","doi-asserted-by":"publisher","first-page":"4251","DOI":"10.1021\/acs.analchem.3c00091","volume":"95","author":"T Rojsajjakul","year":"2023","unstructured":"Rojsajjakul, T. et al. Liquid Chromatography-Mass Spectrometry Analysis of Frataxin Proteoforms in Whole Blood as Biomarkers of the Genetic Disease Friedreich\u2019s Ataxia. Anal. Chem. 95, 4251\u20134260 (2023).","journal-title":"Anal. Chem."},{"key":"5472_CR15","doi-asserted-by":"publisher","first-page":"1815","DOI":"10.3390\/ijms22041815","volume":"22","author":"G Ocana-Santero","year":"2021","unstructured":"Ocana-Santero, G., Diaz-Nido, J. & Herranz-Martin, S. Future Prospects of Gene Therapy for Friedreich\u2019s Ataxia. Int. J. Mol. Sci. 22, 1815 (2021).","journal-title":"Int. J. Mol. Sci."},{"key":"5472_CR16","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1016\/j.ymthe.2020.12.007","volume":"29","author":"JR Mendell","year":"2021","unstructured":"Mendell, J. R. et al. Current Clinical Applications of In Vivo Gene Therapy with AAVs. Mol. Ther. 29, 464\u2013488 (2021).","journal-title":"Mol. Ther."},{"key":"5472_CR17","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1016\/j.omtn.2023.05.014","volume":"32","author":"A Srivastava","year":"2023","unstructured":"Srivastava, A. Rationale and strategies for the development of safe and effective optimized AAV vectors for human gene therapy. Mol. Ther. Nucleic Acids 32, 949\u2013959 (2023).","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"5472_CR18","doi-asserted-by":"publisher","first-page":"103610","DOI":"10.1016\/j.drudis.2023.103610","volume":"28","author":"P Young","year":"2023","unstructured":"Young, P. Treatment to cure: Advancing AAV gene therapy manufacture. Drug Discov. Today 28, 103610 (2023).","journal-title":"Drug Discov. Today"},{"key":"5472_CR19","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1038\/nm.3510","volume":"20","author":"M Perdomini","year":"2014","unstructured":"Perdomini, M. et al. Prevention and reversal of severe mitochondrial cardiomyopathy by gene therapy in a mouse model of Friedreich\u2019s ataxia. Nat. Med. 20, 542\u2013547 (2014).","journal-title":"Nat. Med."},{"key":"5472_CR20","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1089\/hum.2019.363","volume":"31","author":"CO Salami","year":"2020","unstructured":"Salami, C. O. et al. Stress-Induced Mouse Model of the Cardiac Manifestations of Friedreich\u2019s Ataxia Corrected by AAV-mediated Gene Therapy. Hum. Gene Ther. 31, 819\u2013827 (2020).","journal-title":"Hum. Gene Ther."},{"key":"5472_CR21","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/j.omtm.2020.08.018","volume":"19","author":"B Belbellaa","year":"2020","unstructured":"Belbellaa, B., Reutenauer, L., Messaddeq, N., Monassier, L. & Puccio, H. High Levels of Frataxin Overexpression Lead to Mitochondrial and Cardiac Toxicity in Mouse Models. Mol. Ther. Methods Clin. Dev. 19, 120\u2013138 (2020).","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"5472_CR22","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-72884-w","volume":"10","author":"L Weng","year":"2020","unstructured":"Weng, L. et al. Extra-mitochondrial mouse frataxin and its implications for mouse models of Friedreich\u2019s ataxia. Sci. Rep. 10, 15788 (2020).","journal-title":"Sci. Rep."},{"key":"5472_CR23","doi-asserted-by":"publisher","first-page":"1722","DOI":"10.1021\/pr0501721","volume":"4","author":"AK Yocum","year":"2005","unstructured":"Yocum, A. K., Yu, K., Oe, T. & Blair, I. A. Effect of immunoaffinity depletion of human serum during proteomic investigations. J. Proteome Res. 4, 1722\u20131731 (2005).","journal-title":"J. Proteome Res."},{"key":"5472_CR24","doi-asserted-by":"publisher","first-page":"3723","DOI":"10.1002\/rcm.2787","volume":"20","author":"T Oe","year":"2006","unstructured":"Oe, T. et al. Quantitative analysis of amyloid beta peptides in cerebrospinal fluid of Alzheimer\u2019s disease patients by immunoaffinity purification and stable isotope dilution liquid chromatography\/negative electrospray ionization tandem mass spectrometry. Rapid Commun. Mass Spectrom. 20, 3723\u20133735 (2006).","journal-title":"Rapid Commun. Mass Spectrom."},{"key":"5472_CR25","doi-asserted-by":"publisher","first-page":"2895","DOI":"10.4155\/bio.15.195","volume":"7","author":"Q Wang","year":"2015","unstructured":"Wang, Q. et al. Serum apolipoprotein A-1 quantification by LC-MS with a SILAC internal standard reveals reduced levels in smokers. Bioanalysis 7, 2895\u20132911 (2015).","journal-title":"Bioanalysis"},{"key":"5472_CR26","doi-asserted-by":"publisher","first-page":"1804","DOI":"10.1373\/clinchem.2010.152264","volume":"56","author":"SA Agger","year":"2010","unstructured":"Agger, S. A., Marney, L. C. & Hoofnagle, A. N. Simultaneous quantification of apolipoprotein A-I and apolipoprotein B by liquid-chromatography-multiple- reaction-monitoring mass spectrometry. Clin. Chem. 56, 1804\u20131813 (2010).","journal-title":"Clin. Chem."},{"key":"5472_CR27","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.3390\/biom13091335","volume":"13","author":"K Gillespie","year":"2023","unstructured":"Gillespie, K., Pirnie, R., Mesaros, C. & Blair, I. A. Cisplatin Dependent Secretion of Immunomodulatory High Mobility Group Box 1 (HMGB1) Protein from Lung Cancer Cells. Biomolecules 13, 1335 (2023).","journal-title":"Biomolecules"},{"key":"5472_CR28","doi-asserted-by":"publisher","first-page":"7552","DOI":"10.1021\/acs.analchem.8b01175","volume":"90","author":"L Weng","year":"2018","unstructured":"Weng, L., Guo, L., Vachani, A., Mesaros, C. & Blair, I. A. Quantification of Serum High Mobility Group Box 1 by Liquid Chromatography\/High-Resolution Mass Spectrometry: Implications for Its Role in Immunity, Inflammation, and Cancer. Anal. Chem. 90, 7552\u20137560 (2018).","journal-title":"Anal. Chem."},{"key":"5472_CR29","doi-asserted-by":"publisher","first-page":"1893","DOI":"10.1021\/acs.chemrestox.2c00161","volume":"35","author":"R Pirnie","year":"2022","unstructured":"Pirnie, R., Gillespie, K. P., Weng, L., Mesaros, C. & Blair, I. A. Characterization and Quantification of Oxidized High Mobility Group Box 1 Proteoforms Secreted from Hepatocytes by Toxic Levels of Acetaminophen. Chem. Res. Toxicol. 35, 1893\u20131902 (2022).","journal-title":"Chem. Res. Toxicol."},{"key":"5472_CR30","doi-asserted-by":"publisher","first-page":"1731","DOI":"10.1016\/j.ymthe.2017.07.007","volume":"25","author":"S Yla-Herttuala","year":"2017","unstructured":"Yla-Herttuala, S. The Pharmacology of Gene Therapy. Mol. Ther. 25, 1731\u20131732 (2017).","journal-title":"Mol. Ther."},{"key":"5472_CR31","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/j.omtm.2017.12.007","volume":"8","author":"TJ Conlon","year":"2018","unstructured":"Conlon, T. J. & Mavilio, F. The Pharmacology of Gene and Cell Therapy. Mol. Ther. Methods Clin. Dev. 8, 181\u2013182 (2018).","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"5472_CR32","doi-asserted-by":"publisher","first-page":"S79","DOI":"10.1002\/jcph.2141","volume":"62","author":"K Sun","year":"2022","unstructured":"Sun, K. & Liao, M. Z. Clinical Pharmacology Considerations on Recombinant Adeno-Associated Virus-Based Gene Therapy. J. Clin. Pharm. 62, S79\u2013S94 (2022).","journal-title":"J. Clin. Pharm."},{"key":"5472_CR33","unstructured":"FDA. Long Term Follow-Up After Administration of Human Gene Therapy Products. (2020)."},{"key":"5472_CR34","doi-asserted-by":"publisher","DOI":"10.1038\/srep10775","volume":"5","author":"A Koussounadis","year":"2015","unstructured":"Koussounadis, A., Langdon, S. P., Um, I. H., Harrison, D. J. & Smith, V. A. Relationship between differentially expressed mRNA and mRNA-protein correlations in a xenograft model system. Sci. Rep. 5, 10775 (2015).","journal-title":"Sci. Rep."},{"key":"5472_CR35","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2164-9-246","volume":"9","author":"LE Pascal","year":"2008","unstructured":"Pascal, L. E. et al. Correlation of mRNA and protein levels: cell type-specific gene expression of cluster designation antigens in the prostate. BMC Genom. 9, 246 (2008).","journal-title":"BMC Genom."},{"key":"5472_CR36","doi-asserted-by":"publisher","first-page":"e0276294","DOI":"10.1371\/journal.pone.0276294","volume":"17","author":"BP Nicolet","year":"2022","unstructured":"Nicolet, B. P. & Wolkers, M. C. The relationship of mRNA with protein expression in CD8+ T cells associates with gene class and gene characteristics. PLoS One 17, e0276294 (2022).","journal-title":"PLoS One"},{"key":"5472_CR37","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/j.cell.2016.03.014","volume":"165","author":"Y Liu","year":"2016","unstructured":"Liu, Y., Beyer, A. & Aebersold, R. On the Dependency of Cellular Protein Levels on mRNA Abundance. Cell 165, 535\u2013550 (2016).","journal-title":"Cell"},{"key":"5472_CR38","doi-asserted-by":"publisher","first-page":"eabm1890","DOI":"10.1126\/sciadv.abm1890","volume":"8","author":"TP Cripe","year":"2022","unstructured":"Cripe, T. P. et al. Leveraging gene therapy to achieve long-term continuous or controllable expression of biotherapeutics. Sci. Adv. 8, eabm1890 (2022).","journal-title":"Sci. Adv."},{"key":"5472_CR39","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1016\/j.omtm.2022.10.011","volume":"27","author":"A Burr","year":"2022","unstructured":"Burr, A. et al. Allometric-like scaling of AAV gene therapy for systemic protein delivery. Mol. Ther. Methods Clin. Dev. 27, 368\u2013379 (2022).","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"5472_CR40","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1038\/s41586-021-03770-2","volume":"596","author":"AM Monteys","year":"2021","unstructured":"Monteys, A. M. et al. Regulated control of gene therapies by drug-induced splicing. Nature 596, 291\u2013295 (2021).","journal-title":"Nature"},{"key":"5472_CR41","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-023-02619-3","volume":"18","author":"EJ Vallender","year":"2023","unstructured":"Vallender, E. J. et al. Nonhuman primate genetic models for the study of rare diseases. Orphanet J. Rare Dis. 18, 20 (2023).","journal-title":"Orphanet J. Rare Dis."},{"key":"5472_CR42","doi-asserted-by":"publisher","first-page":"105332","DOI":"10.1016\/j.yrtph.2022.105332","volume":"138","author":"P Baldrick","year":"2023","unstructured":"Baldrick, P., McIntosh, B. & Prasad, M. Adeno-associated virus (AAV)-based gene therapy products: What are toxicity studies in non-human primates showing us? Regul. Toxicol. Pharm. 138, 105332 (2023).","journal-title":"Regul. Toxicol. Pharm."},{"key":"5472_CR43","doi-asserted-by":"publisher","first-page":"2242","DOI":"10.1016\/j.neuron.2022.05.003","volume":"110","author":"X Chen","year":"2022","unstructured":"Chen, X. et al. Engineered AAVs for non-invasive gene delivery to rodent and non-human primate nervous systems. Neuron 110, 2242\u20132257.e2246 (2022).","journal-title":"Neuron"},{"key":"5472_CR44","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1089\/hum.1997.8.10-1195","volume":"8","author":"DE Sullivan","year":"1997","unstructured":"Sullivan, D. E. et al. Liver-directed gene transfer in non-human primates. Hum. Gene Ther. 8, 1195\u20131206 (1997).","journal-title":"Hum. Gene Ther."},{"key":"5472_CR45","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1016\/j.omtm.2022.02.002","volume":"24","author":"C Huichalaf","year":"2022","unstructured":"Huichalaf, C. et al. In vivo overexpression of frataxin causes toxicity mediated by iron-sulfur cluster deficiency. Mol. Ther. Methods Clin. Dev. 24, 367\u2013378 (2022).","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"5472_CR46","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1080\/10409230600846058","volume":"41","author":"KZ Bencze","year":"2006","unstructured":"Bencze, K. Z. et al. The structure and function of frataxin. Crit. Rev. Biochem Mol. Biol. 41, 269\u2013291 (2006).","journal-title":"Crit. Rev. Biochem Mol. Biol."},{"key":"5472_CR47","doi-asserted-by":"publisher","first-page":"2216","DOI":"10.1021\/acs.analchem.7b04590","volume":"90","author":"L Guo","year":"2018","unstructured":"Guo, L. et al. Liquid chromatography-high resolution mass spectrometry analysis of platelet frataxin as a protein biomarker for the rare disease Friedreich\u2019s Ataxia. Anal. Chem. 90, 2216\u20132223 (2018).","journal-title":"Anal. Chem."},{"key":"5472_CR48","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.1089\/hum.2010.055","volume":"21","author":"M Lock","year":"2010","unstructured":"Lock, M. et al. Rapid, simple, and versatile manufacturing of recombinant adeno-associated viral vectors at scale. Hum. Gene Ther. 21, 1259\u20131271 (2010).","journal-title":"Hum. Gene Ther."},{"key":"5472_CR49","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1089\/hgtb.2013.131","volume":"25","author":"M Lock","year":"2014","unstructured":"Lock, M., Alvira, M. R., Chen, S. J. & Wilson, J. M. Absolute determination of single-stranded and self-complementary adeno-associated viral vector genome titers by droplet digital PCR. Hum. Gene Ther. Methods 25, 115\u2013125 (2014).","journal-title":"Hum. Gene Ther. Methods"},{"key":"5472_CR50","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1002\/mas.21540","volume":"39","author":"LK Pino","year":"2020","unstructured":"Pino, L. K. et al. The Skyline ecosystem: Informatics for quantitative mass spectrometry proteomics. Mass Spectrom. Rev. 39, 229\u2013244 (2020).","journal-title":"Mass Spectrom. Rev."}],"container-title":["Communications Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s42003-023-05472-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s42003-023-05472-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s42003-023-05472-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,27]],"date-time":"2023-10-27T15:08:20Z","timestamp":1698419300000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s42003-023-05472-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,27]]},"references-count":50,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["5472"],"URL":"https:\/\/doi.org\/10.1038\/s42003-023-05472-z","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-3121549\/v1","asserted-by":"object"}]},"ISSN":["2399-3642"],"issn-type":[{"value":"2399-3642","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,27]]},"assertion":[{"value":"10 July 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 October 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 October 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare the following competing interests: J.M.W is a paid advisor to and holds equity in iECURE, Scout Bio, Passage Bio, and the Center for Breakthrough Medicines (CBM). He also holds equity in the former G2 Bio asset companies. He has sponsored research agreements with Amicus Therapeutics, CBM, Elaaj Bio, FA212, former G2 Bio asset companies, iECURE, Passage Bio, and Scout Bio, which are licensees of Penn technology. C.J.H. holds equity in Scout Bio and a former G2 Bio asset company. J.M.W., C.J.H, and J.J.H, are inventors on patents that have been licensed to various biopharmaceutical companies and for which they may receive payments. I.A.B. has sponsored research agreements with Lexeo Therapeutics and Design Therapeutics. All other authors declare no competing interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1093"}}